[go: up one dir, main page]

SI1711530T1 - Imunoglobulini, ki nevtralizirajo NogoA, za zdravljenje nevroloških bolezni - Google Patents

Imunoglobulini, ki nevtralizirajo NogoA, za zdravljenje nevroloških bolezni

Info

Publication number
SI1711530T1
SI1711530T1 SI200431272T SI200431272T SI1711530T1 SI 1711530 T1 SI1711530 T1 SI 1711530T1 SI 200431272 T SI200431272 T SI 200431272T SI 200431272 T SI200431272 T SI 200431272T SI 1711530 T1 SI1711530 T1 SI 1711530T1
Authority
SI
Slovenia
Prior art keywords
nogo
neutralising
immunoglobulins
treatment
neurological diseases
Prior art date
Application number
SI200431272T
Other languages
English (en)
Inventor
Jonathan Henry Ellis
Alexandre Eon-Duval
Robert Ian Grundy
Farhana Hussain
Ruth Mcadam
Christopher Plumpton
Rabinder Kumar Prinjha
Paul Alexander Wilson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0329684A external-priority patent/GB0329684D0/en
Priority claimed from GB0329711A external-priority patent/GB0329711D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SI1711530T1 publication Critical patent/SI1711530T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200431272T 2003-12-22 2004-12-20 Imunoglobulini, ki nevtralizirajo NogoA, za zdravljenje nevroloških bolezni SI1711530T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0329684A GB0329684D0 (en) 2003-12-22 2003-12-22 Method
GB0329711A GB0329711D0 (en) 2003-12-22 2003-12-22 Antibodies
EP04806128A EP1711530B1 (en) 2003-12-22 2004-12-20 Nogo-a neutralising immunoglobulins for treatment of neurological diseases
PCT/GB2004/005325 WO2005061544A2 (en) 2003-12-22 2004-12-20 Nogo-a neutralising immunoglobulins for treatment of neurological diseases

Publications (1)

Publication Number Publication Date
SI1711530T1 true SI1711530T1 (sl) 2010-01-29

Family

ID=34712703

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200431272T SI1711530T1 (sl) 2003-12-22 2004-12-20 Imunoglobulini, ki nevtralizirajo NogoA, za zdravljenje nevroloških bolezni

Country Status (27)

Country Link
US (4) US7988964B2 (sl)
EP (3) EP2213684A3 (sl)
JP (2) JP2007537145A (sl)
KR (1) KR101150548B1 (sl)
AR (1) AR048912A1 (sl)
AT (1) ATE440866T1 (sl)
AU (1) AU2004303585B2 (sl)
BR (1) BRPI0417959A (sl)
CA (1) CA2549956C (sl)
CY (1) CY1110530T1 (sl)
DE (1) DE602004022871D1 (sl)
DK (1) DK1711530T3 (sl)
ES (1) ES2330444T3 (sl)
HR (1) HRP20090527T1 (sl)
IL (1) IL176206A (sl)
IS (1) IS2739B (sl)
MA (1) MA28289A1 (sl)
MX (1) MXPA06007190A (sl)
MY (1) MY144612A (sl)
NO (1) NO20062767L (sl)
NZ (1) NZ548013A (sl)
PL (1) PL1711530T3 (sl)
PT (1) PT1711530E (sl)
RU (1) RU2362780C2 (sl)
SI (1) SI1711530T1 (sl)
TW (1) TWI329649B (sl)
WO (2) WO2005061544A2 (sl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4986370B2 (ja) 2000-12-22 2012-07-25 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ Ｒｇｍおよびそのモジュレーターの用途
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
CA2549956C (en) * 2003-12-22 2016-04-12 Glaxo Group Limited Immunoglobulins
NZ564567A (en) * 2005-07-05 2010-09-30 Glaxo Group Ltd Humanised antibodies specific for neurite outgrowth inhibitor-A and pharmaceutical uses thereof
EP1928905B1 (de) 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
GB0525662D0 (en) * 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
US8663635B2 (en) 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
US20090291976A1 (en) * 2006-06-27 2009-11-26 Peter Andrew Ferchmin Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
KR20140119831A (ko) * 2006-12-07 2014-10-10 노파르티스 아게 Ｅｐｈｂ３에 대한 길항제 항체
WO2008104386A2 (en) * 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
WO2009026117A2 (en) * 2007-08-16 2009-02-26 Glaxo Group Limited Novel compounds
ES2425768T3 (es) * 2007-11-02 2013-10-17 Novartis Ag Moléculas de unión a nogo-a mejoradas y uso farmacéutico de las mismas
US8962803B2 (en) * 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
EA201001603A1 (ru) * 2008-04-04 2011-06-30 Те Риджентс Оф Те Юниверсити Оф Калифорния Антитела против кадгерина, блокирующие рост опухоли, ангиогенез и метастазирование
WO2010004031A2 (en) * 2008-07-11 2010-01-14 Glaxo Group Limited Novel treatment
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
KR20120118002A (ko) 2009-12-08 2012-10-25 애보트 게엠베하 운트 콤파니 카게 망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
WO2012004773A1 (en) 2010-07-09 2012-01-12 Universite De Geneve New uses of nogo-a inhibitors and related methods
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
CA2817973C (en) 2010-10-15 2019-06-25 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
AU2011320314B2 (en) 2010-10-29 2015-08-06 Immunogen, Inc. Novel EGFR-binding molecules and immunoconjugates thereof
EA201390575A1 (ru) 2010-10-29 2014-01-30 Иммьюноджен, Инк. Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
SG11201402343SA (en) 2011-11-21 2014-06-27 Immunogen Inc Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
CA2863224A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
PE20190907A1 (es) 2012-01-27 2019-06-26 AbbVie Deutschland GmbH and Co KG Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
CN104395343A (zh) 2012-07-05 2015-03-04 葛兰素集团有限公司 抗Nogo-A抗体在肌萎缩侧索硬化治疗中的最佳剂量方案
AU2016257929B2 (en) 2015-05-04 2022-10-20 Cytomx Therapeutics, Inc Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
US11220544B2 (en) * 2017-07-14 2022-01-11 Cytomx Therapeutics, Inc. Anti-CD166 antibodies and uses thereof
TW201946654A (zh) 2018-03-05 2019-12-16 比利時商健生藥品公司 抗ＰＨＦ－Ｔａｕ抗體及其用途
WO2020068058A1 (en) * 2018-09-25 2020-04-02 Academia Sinica Anti-siglec antibody, pharmaceutical composition comprising the same, and uses thereof
CN114599676A (zh) * 2019-10-24 2022-06-07 诺华康制药股份公司 新型抗-Nogo-A抗体
EP4255932A4 (en) * 2020-12-02 2024-11-13 Agilent Technologies, Inc. Anti-human cd10 antibodies for use in immunohistochemistry (ihc) protocols to diagnose cancer
WO2024041450A1 (zh) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用
CN116693672B (zh) * 2023-06-15 2025-08-08 郑州伊美诺生物技术有限公司 抗3型人副流感病毒单克隆抗体及其制备方法和应用
WO2025006549A2 (en) * 2023-06-28 2025-01-02 University Of Connecticut Antibodies against immune checkpoint molecules and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3935074A (en) * 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
CA2191352C (en) 1994-05-27 2001-01-30 Carlo Farina Quinoline derivatives as tachykinin nk3 receptor antagonists
HUP0301829A3 (en) * 1998-11-06 2009-03-30 Schwab Nucleotidok and protein sequences of nogo genes and methods based thereon
FR2792199B3 (fr) 1999-04-13 2001-05-18 Sanofi Sa Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
US20030113891A1 (en) * 2000-02-11 2003-06-19 Lawrence Blatt Method and reagent for the inhibition of NOGO and NOGO receptor genes
GB0101313D0 (en) * 2001-01-18 2001-02-28 Glaxo Group Ltd Assay
JP2006500006A (ja) * 2002-04-17 2006-01-05 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー アルツハイマー病を治療する組成物および方法
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
AU2004231742A1 (en) * 2003-04-16 2004-11-04 Biogen Idec Ma Inc. Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
CA2549956C (en) * 2003-12-22 2016-04-12 Glaxo Group Limited Immunoglobulins

Also Published As

Publication number Publication date
PL1711530T3 (pl) 2010-01-29
WO2005061545A3 (en) 2005-08-18
DK1711530T3 (da) 2009-12-14
WO2005061544A3 (en) 2005-08-18
US20070065430A1 (en) 2007-03-22
TWI329649B (en) 2010-09-01
CA2549956C (en) 2016-04-12
US7780964B2 (en) 2010-08-24
KR20060129290A (ko) 2006-12-15
RU2006123481A (ru) 2008-01-27
AU2004303585B2 (en) 2010-12-23
DE602004022871D1 (de) 2009-10-08
EP1706426A2 (en) 2006-10-04
US20110054149A1 (en) 2011-03-03
RU2362780C2 (ru) 2009-07-27
NO20062767L (no) 2006-09-20
IL176206A (en) 2012-02-29
WO2005061545A2 (en) 2005-07-07
CY1110530T1 (el) 2015-04-29
IL176206A0 (en) 2006-10-05
JP2008504220A (ja) 2008-02-14
EP1711530A2 (en) 2006-10-18
CA2549956A1 (en) 2005-07-07
IS2739B (is) 2011-06-15
PT1711530E (pt) 2009-10-22
NZ548013A (en) 2009-04-30
ATE440866T1 (de) 2009-09-15
EP2213684A2 (en) 2010-08-04
EP2213684A3 (en) 2011-05-18
TW200533680A (en) 2005-10-16
JP4901480B2 (ja) 2012-03-21
AR048912A1 (es) 2006-06-14
MA28289A1 (fr) 2006-11-01
US20140147435A1 (en) 2014-05-29
ES2330444T3 (es) 2009-12-10
IS8506A (is) 2006-06-12
MXPA06007190A (es) 2006-08-23
KR101150548B1 (ko) 2012-07-06
AU2004303585A1 (en) 2005-07-07
WO2005061544A2 (en) 2005-07-07
US7988964B2 (en) 2011-08-02
HK1100144A1 (en) 2007-09-07
JP2007537145A (ja) 2007-12-20
US20060029603A1 (en) 2006-02-09
EP1711530B1 (en) 2009-08-26
MY144612A (en) 2011-10-14
BRPI0417959A (pt) 2007-03-27
HRP20090527T1 (hr) 2009-11-30

Similar Documents

Publication Publication Date Title
IL176206A0 (en) Nogo-a neutralising immunoglobulins for treatment of neurological diseases
ZA200508427B (en) Methods for treating interleuking-6 related diseases
IL176407A0 (en) Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
SG10201912182UA (en) Improved modalities for the treatment of degenerative diseases of the retina
PL397229A1 (pl) Benzodiazepinowe pochodne do leczenia chorób neurologicznych
GB0329874D0 (en) Compounds useful for the treatment of diseases
EP1680145A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
IL175535A0 (en) Compositions for treatment of neurodegenerative diseases
EP1611120A4 (en) NEW M THODES FOR THE TREATMENT OF INFLAMMATORY DISEASES
GB0320238D0 (en) Treatment of disease
IL175814A0 (en) Triazine dimers for the treatment of autoimmune diseases
ZA200605075B (en) NOGO-A neutralising immunoglobulins for treatment of neurological diseases
GB0400802D0 (en) Compounds for the treatment of disease
IL175412A0 (en) Use of specific histones for the treatment of parasitic diseases
TWI349549B (en) Medicament for treatment of intraocular angiopoietic disease
ZA200606780B (en) Compounds for the treatment of diseases
AU2003300471A8 (en) Methods for treating ocular diseases
GB0425073D0 (en) Compounds for the treatment of diseases
IL177531A0 (en) Compounds for the treatment of diseases
GB0420867D0 (en) Compounds for the treatment of diseases
IL175611A0 (en) Combinations for the treatment of proliferative diseases
HU0302933D0 (en) Treatment of diseases
AP2006003743A0 (en) Compounds useful for the treatment of diseases
GB0425064D0 (en) Compounds useful for the treatment of diseases